Dinalbuphine sebacate
- Generic Name
- Dinalbuphine sebacate
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C52H68N2O10
- CAS Number
- 311768-81-7
- Unique Ingredient Identifier
- 464OXX39Y6
- Background
Dinalbuphine sebacate is under investigation in clinical trial NCT02468128 (A Study of Intramuscular Sebacoyl Dinalbuphine Ester for Post-Hemorrhoidectomy Pain Management).
- Associated Conditions
- -
- Associated Therapies
- -
Postoperative Pain Management on Patients Undergoing Lung Tumor Resection
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-05-03
- Last Posted Date
- 2024-05-03
- Lead Sponsor
- China Medical University Hospital
- Target Recruit Count
- 400
- Registration Number
- NCT06397807
Postoperative Pain Management on Uvulopalatopharyngoplasty Patients
Phase 4
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-04-24
- Last Posted Date
- 2023-04-25
- Lead Sponsor
- Li-Jen Hsin
- Target Recruit Count
- 78
- Registration Number
- NCT05825495
Naldebain® Extended-release Injection After Cesarean Section in Pain Management
- Conditions
- Interventions
- First Posted Date
- 2022-07-06
- Last Posted Date
- 2022-07-06
- Lead Sponsor
- Tri-Service General Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT05446311
Postoperative Pain Management of Caesarean Section
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2021-08-18
- Last Posted Date
- 2023-10-23
- Lead Sponsor
- Mackay Memorial Hospital
- Target Recruit Count
- 150
- Registration Number
- NCT05009771
- Locations
- 🇨🇳
MacKay Memorial Hospital, Taipei, Taiwan
🇨🇳MacKay Memorial Hospital Tamsui Branch, New Taipei City, Taiwan
Naldebain for Pain Management of Laparoscopic Cholecystectomy
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2021-03-22
- Last Posted Date
- 2022-04-20
- Lead Sponsor
- E-DA Hospital
- Target Recruit Count
- 80
- Registration Number
- NCT04808544
- Locations
- 🇨🇳
E-Da Hospital, Yanchao, Kaohsiung, Taiwan
Naldebain for Pain Control After Bariatric Surgery
- First Posted Date
- 2020-12-03
- Last Posted Date
- 2021-12-28
- Lead Sponsor
- E-DA Hospital
- Target Recruit Count
- 60
- Registration Number
- NCT04651361
- Locations
- 🇨🇳
E-Da Hospital, Yanchao, Kaohsiung, Taiwan
A Bioavailability Study of NALDEBAIN ER Injection and Nalbuphine Injection in Healthy Volunteers.
- First Posted Date
- 2020-02-05
- Last Posted Date
- 2021-11-19
- Lead Sponsor
- Lumosa Therapeutics Co., Ltd.
- Target Recruit Count
- 24
- Registration Number
- NCT04256434
- Locations
- 🇺🇸
WCCT Global Inc., Cypress, California, United States
The Efficacy and Safety of NALDEBAIN for the Treatment of Post-Laparotomy Surgery
- First Posted Date
- 2017-09-28
- Last Posted Date
- 2017-09-28
- Target Recruit Count
- 110
- Registration Number
- NCT03296488
- Locations
- 🇨🇳
Chung-Ho Memorial Hospital, Kaohsiung Medical University:, Kaohsiung, Taiwan
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath